Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Chimeric Therapeutics has announced the re-opening of enrolment for its Phase 1B study combining CHM CORE-NK, an innovative off-the-shelf NK cell therapy, with vactosertib for patients with advanced colorectal cancer and relapsed blood cancers. The move comes after a temporary pause due to resource constraints, with the company aiming to build on the promising safety and efficacy signals observed in earlier trials. Chimeric Therapeutics continues to lead advancements in cell therapy without financial support for this trial.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.
